Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Seres Therapeutics Announces Positive Topline Results From SER-109 Phase 3 ECOSPOR III Study In Recurrent C. Difficile Infection

Seres Therapeutics 08.13.2020

Omega Therapeutics Advances Controllable Epigenomic Programming Platform to Deliver a Pipeline of Novel Therapeutics with $85M in Financing

Omega Therapeutics 07.29.2020

Flagship Pioneering’s Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

Tessera Therapeutics 07.07.2020

Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

Cellarity 05.28.2020

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Moderna 05.18.2020

Repertoire Immune Medicines Strengthens Executive Team; Names Biotech Industry Veterans to Key Roles

Repertoire Immune Medicines 04.23.2020

Flagship Pioneering Completes Raising a New $1.1 Billion Capital Pool

Flagship Pioneering 04.02.2020

Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund

Repertoire Immune Medicines 03.25.2020

Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors

Seres Therapeutics 03.23.2020

Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer

Repertoire Immune Medicines 03.12.2020

Loading